Regentis (RGNT) CEO Ehud Geller Receives 31,250 Warrants

What Happened
Ehud Geller, CEO of Regentis Biomaterials (RGNT), received an award of 31,250 warrants on July 9, 2026. The award is recorded as a derivative acquisition with an acquisition price of $0.00 (i.e., no cash paid at grant). This is a grant of rights to purchase shares in the future (an award), not an open‑market purchase or sale.

Key Details

• Transaction date: July 9, 2026. Report filed with the SEC on July 13, 2026 (within the normal two‑business‑day Form 4 filing window).
• Transaction code: A (award/grant). Acquisition amount reported: 31,250 warrants at $0.00.
• Post‑transaction holdings: Not specified in the provided filing excerpt.
• Footnotes: Board approved the warrant grant on Feb 23, 2026, subject to shareholder approval, which shareholders provided on July 9, 2026 (F1). The warrants are currently exercisable and have a three‑year term (F2).

Context
Warrants are derivatives that give the holder the right to buy company shares later at a specified exercise price. This filing reflects receipt of the warrants (an award) rather than an immediate exercise or sale; it does not by itself indicate buying or selling pressure. No exercise price or immediate cash proceeds were reported in the provided excerpt.